Skip to main navigation

    Library: Global (English)  Life Sciences - 21
    Next >>





    AdvaMed 2014: hot topics
    (pdf, 145.33 KB)
    04 Nov, 2014 Global

    Commoditization is real, and differentiation is an imperative

    EY - Worldwide-randd-incentives-reference-guide Worldwide R&D incentives reference guide 2014-2015
    (pdf, 8.33 MB)
    31 Oct, 2014 Global

    Our latest guide offers a description of available benefits, the incentive application process, eligibility and IP jurisdictional requirements. Learn about the latest R&D incentives.

    (pdf, 906.27 KB)
    31 Oct, 2014 Global

    EY's Jeff Greene and Andrew Forman comment on deal activity in INVIVO's September 2014 issue "M&A tops 2009 merger mania"

    To the Point
    (pdf, 85.87 KB)
    30 Oct, 2014 Global

    Learn how final regulations issued by the IRS will change the way pharma manufacturers account for the annual branded prescription drug fee.

    Technical Line - Aug - 2014
    (pdf, 130.59 KB)
    26 Sep, 2014 Global

    The new revenue recognition standard - life sciences

    EY - Pulse of the industry Pulse of the industry - Medical technology report 2014
    (pdf, 4,30 MB)
    15 Sep, 2014 Global

    EY Pulse of the industry - Medical technology report 2014

    EY- Cash on prescription Cash on prescription - 2014
    (pdf, 793.57 KB)
    04 Jul, 2014 Global

    Pharma saw improved working capital performance in 2013, but progress has not been sufficient to reverse deterioration of previous years. Our report explores.

    EY - Beyond borders 2014 cover Beyond borders unlocking value
    (pdf, 2.51 MB)
    23 Jun, 2014 Global

    EY - Beyond borders unlocking value

    EY - Biotechnology in europe cover Biotechnology in Europe
    (pdf, 2,74 MB)
    12 Jun, 2014 Global

    EY - Biotechnology in europe

    EY - Progressions: Navigating the payer landscape Progressions 2014: Navigating the payer landscape
    (pdf, 1,99 MB)
    06 May, 2014 Global

    For pharmaceutical companies, a fragmented and rapidly changing payer universe poses challenges and raises some key questions. Our pharma report explores.

    Next >>
    Back to top